Search
Ibrigampar
go.drugbank.com/drugs/DB05490InvestigationalAMG-131 (T131), an orally-administered therapy, is expected to lower blood glucose in type II diabetic patients by improving the body’s ability to respond to insulin. … T131 is a selective modulator of PPARg (peroxisome proliferator activated receptor gamma), a receptor involved in regulating the body’s ability to respond to insulin.
RI 624
go.drugbank.com/drugs/DB05892ExperimentalRI 624 is being developed by Rinat and is currently in Phase I clinical trials.
YKP-1358
go.drugbank.com/drugs/DB06109ExperimentalYKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeIMC-1C11
go.drugbank.com/drugs/DB06101ExperimentalIMC-1C11 is used for treatment of patients with liver metastases from colorectal carcinoma.
Hyaluronidase (ovine)
go.drugbank.com/drugs/DB00070ApprovedHighly purified sheep hyaluronidase for administration by injection into the vitreous of the eye.
NE-180
go.drugbank.com/drugs/DB05619ExperimentalNE-180 was under investigation in a clinical trial conducted in the European Union.
Clofedanol
go.drugbank.com/drugs/DB04837ApprovedWithdrawnClofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States.
Mixtures: Ninjacof Cotton Candy Flavor- 16 ozHY10275
go.drugbank.com/drugs/DB05079ExperimentalHY10275 was rationally designed to "let you sleep" rather than depress the entire brain to "make you sleep." … HY10275 is highly selective for histamine H1 and serotonin 5HT2a, two chemical receptors that are known to impact the ability to fall asleep and stay asleep.
SKF-96365 free base
go.drugbank.com/drugs/DB17054ExperimentalSKF-96365 is a receptor-mediated calcium entry (RMCE) inhibitor structurally different from other calcium antagonists.[A253132]
TL-895
go.drugbank.com/drugs/DB16471InvestigationalTL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. … TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B